— Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected.
— Total revenue remained flat at $5.60 billion, vs. $5.61 billion expected. Total product sales were flat at 5.5 billion.
— Narrowed full year 2019 guidance on sales to $21.8-22.1 billion, from earlier esimtate of $21.6-22.1 billion.
— GILD shares have been trading sideways since the beginning of this year. The stock has so far declined 3% this year.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Kroger (KR) looks set to start 2023 with new vigor. Is the stock a buy?
The retail environment has witnessed many changes in customers’ shopping behavior lately, especially after the COVID outbreak. With inflation putting pressure on personal finances, there appears to be a new
Dollar General (DG): Five takeaways from the discount store’s Q3 earnings report
Shares of Dollar General Corporation (NYSE: DG) were up over 2% on Friday, a day after the company delivered mixed results for the third quarter of 2022 and lowered its
Salesforce stock hit by weak guidance, co-CEO’s exit. What next?
For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected
